Withdrawal of testosterone to affect thousands

Users of roll-on formulation need to switch

The withdrawal from the market of a transdermal testosterone product will force about 2500 men to switch to alternatives within the next few weeks, an endocrinologist says.


A roll-on formulation of testosterone, Axiron, which is used by about 10% of men on androgen replacement therapy, will not be available from 4 December after being discontinued for commercial reasons.

Melbourne endocrinologist Dr Carolyn Allan says this means patients will need to secure an alternative prescription and may need their GP to help.

“They’ll notice when they fill the next